A clinically supervised treatment to filter your blood, clear harmful molecules, and support healthy ageing
Therapeutic Plasma Exchange (TPE) is a medically supervised treatment that works by gently filtering your blood, removing harmful proteins, inflammatory molecules, and ageing-associated factors that accumulate over time and drive disease. At Reborne, TPE is only offered following a thorough clinical assessment and is delivered with the same rigour as any hospital procedure.
We currently use TPE to support clients across five clinical pathways: biological age reversal, autoimmune conditions, moderate Alzheimer's disease, elevated Lipoprotein(a), and toxin or heavy metal burden.
Why Plasma Matters
Your blood plasma is more than just a carrier fluid. It transports proteins, fats, immune molecules, inflammatory signals, environmental toxins, and cellular instructions around the body. In certain conditions, harmful versions of these molecules build up in the bloodstream and actively drive disease and accelerated ageing. TPE works by physically removing them, giving your body a cleaner internal environment to function in.
How the Procedure Works
A small amount of blood is drawn from a vein and passed through a medical-grade filtering machine. This separates your plasma (the liquid part of your blood) from your red and white blood cells. The plasma, which contains the harmful molecules we are targeting, is removed and replaced with a safe and carefully selected replacement fluid. Your blood cells are then returned to your body, clean and replenished.
Think of it as a deep cleanse for your bloodstream, removing the molecules that no longer serve you and returning your cells in a healthier environment.
.png)
What to Expect
Each session takes between 90 minutes and 3 hours, during which you will be comfortably seated or reclined in one of our private treatment rooms. You will be monitored throughout by our clinical team. Most clients feel perfectly comfortable during the procedure, similar to a long IV infusion. It is normal to feel tired for a day or so afterwards, so we recommend keeping the rest of your day relaxed. Our team will advise you on any preparation or aftercare specific to your treatment plan.
Treatment Pathways
TPE is not a one-size-fits-all treatment. Our clinical team will determine which pathway, if any, is appropriate for you following a thorough consultation and diagnostic review. Each pathway below is supported by a distinct and growing body of clinical evidence.
Pathway 1: Biological Age Reversal
Beyond its established medical applications, TPE has now been shown in a landmark placebo- controlled human trial to measurably reverse biological age, making it one of the very few interventions with robust clinical evidence for age-related molecular rejuvenation.
The Buck Institute Trial, 2025
In May 2025, researchers at the Buck Institute for Research on Aging, one of the world's leading institutions dedicated to ageing science, published the results of the first randomised, placebo- controlled human trial to assess TPE's impact on biological age using comprehensive molecular profiling. The results were published in the peer-reviewed journal Aging Cell.
Forty-two healthy adults over 50 were assigned to receive biweekly TPE combined with intravenous immunoglobulin (IVIG), biweekly TPE alone, monthly TPE, or a placebo. Biological age was tracked using 36 validated epigenetic clocks alongside a full multi-omics panel covering the genome, proteins, metabolites, immune cells, and inflammatory markers.
2.61 years
average biological age reduction with TPE combined with IVIG (placebo-controlled trial, Aging Cell 2025)
Participants receiving monthly TPE alone showed an average biological age reduction of 1.32 years. Both groups significantly outperformed the placebo group. Importantly, the inflammatory and immune clocks showed the most dramatic reversals, with some participants experiencing the equivalent of 7 to 10 years of immune age rejuvenation.
What changed at the molecular level: The treatment produced coordinated improvements across the epigenome, proteome, metabolome, and immune cell composition simultaneously, indicating a broad systemic rejuvenation rather than changes to a single marker.
Who benefited most: Participants with higher baseline levels of circulating glucose, bilirubin, or inflammatory markers saw the greatest reductions in biological age. This supports a personalised approach where clients with greater biological age acceleration may derive the most benefit.
Physical performance: Beyond molecular markers, participants showed measurable improvements in balance and strength, suggesting the biological changes translate into functional gains.
A note on clinical context
The trial was exploratory in scale and the authors appropriately describe it as hypothesis-generating. At Reborne, we present this evidence clearly and honestly to clients. TPE for biological age optimisation is offered within a fully supervised medical framework, with detailed discussion of what the current evidence does and does not yet show.
Pathway 2: Autoimmune and Immune-Mediated Conditions
In autoimmune conditions, the immune system mistakenly produces proteins called autoantibodies that attack the body's own tissues. These circulate in the blood and can cause significant and progressive damage over time. TPE can rapidly reduce the levels of these harmful immune proteins, offering meaningful relief where other treatments may be slow or insufficient.
This is one of the most established applications of TPE. International medical guidelines from the American Society for Apheresis recognise TPE as a first-line or adjunctive therapy for a range of antibody-driven conditions including myasthenia gravis, Guillain-Barre syndrome, neuromyelitis optica, and lupus-related complications. The evidence base spans multiple randomised controlled trials and Cochrane reviews going back decades.
Evidence
International guidelines recognise TPE as a first-line or adjunctive therapy in selected autoimmune and neurological conditions. Key reference: Schwartz J et al., Journal of Clinical Apheresis, 2016.
Pathway 3: Alzheimer's Disease (Moderate Stage)
One of the hallmarks of Alzheimer's disease is the accumulation of a protein called amyloid in the brain. Research shows that amyloid in the brain and amyloid in the bloodstream are in constant balance with each other. By reducing amyloid levels in the blood through TPE, we may be able to encourage the brain to offload some of its own amyloid burden, a concept known as the peripheral sink effect.
The AMBAR clinical trial, published in Alzheimer's and Dementia in 2020, demonstrated a 66% reduction in cognitive decline and a 52% preservation of daily function in patients who received plasma exchange compared to placebo. This is one of the more promising clinical trial results in Alzheimer's research in recent years.
Alzheimer's disease is not yet a fully established indication for TPE, and at Reborne it is offered on a carefully assessed, individual basis following comprehensive neurological evaluation. It is not presented as a cure, but as a clinically supervised intervention with a meaningful and growing evidence base.
Evidence
Clinical trials including the AMBAR study have explored plasma exchange with albumin replacement in Alzheimer's disease, demonstrating biological effects on amyloid dynamics. Key references: Boada M et al., Alzheimer's and Dementia, 2020; Sagare AP et al., Nature Reviews Neurology, 2012.
Pathway 4: Elevated Lipoprotein(a) and Cardiovascular Risk
Lipoprotein(a), or Lp(a), is a type of cholesterol particle that significantly raises the risk of heart attack and stroke. Unlike standard cholesterol, Lp(a) is largely determined by your genes, meaning diet, exercise, and most medications have very little effect on it.
For people with very high Lp(a) levels who are at serious cardiovascular risk despite optimised treatment, TPE is one of the few interventions available that can produce meaningful reductions. Published apheresis literature consistently demonstrates acute Lp(a) reductions of 60 to 75% per session in selected patients. We will assess your full cardiovascular profile, including genetic lipid testing, before recommending this pathway.
Evidence
Apheresis techniques can significantly reduce circulating Lp(a) in selected patients. Key references: Moriarty PM et al., Journal of Clinical Lipidology, 2019; Tsimikas S, Journal of the American College of Cardiology, 2017.
Pathway 5: Toxin and Heavy Metal Burden
A less widely known but clinically supported application of TPE is the removal of protein-bound environmental toxins, heavy metals, and other large-molecular-weight substances that the body struggles to clear naturally through the liver and kidneys alone.
Many environmental toxins, including heavy metals such as lead and mercury, mycotoxins from mould exposure, and certain persistent environmental chemicals, bind to plasma proteins when they circulate in the bloodstream. Because standard detoxification pathways rely on the liver and kidneys breaking substances down, they are often poorly equipped to clear these protein-bound compounds efficiently. TPE takes a different approach: by physically removing the plasma itself, it can directly extract these bound toxins along with the plasma that carries them.
Heavy metals: Clinical reports have documented measurable reductions in circulating heavy metals including lead and mercury following TPE, particularly in cases of documented accumulation where conventional detoxification support has been inadequate.
Mycotoxins: TPE has been used in cases of significant mould-related illness to reduce circulating mycotoxins, which can have both neurotoxic and immune-suppressive effects.
Environmental chemicals: Emerging clinical data supports the use of TPE in cases of high environmental pollutant burden including organophosphates and persistent organic compounds.
In selected cases, Reborne may also use a more targeted technique called Double Filtration Plasmapheresis (DFPP), which employs a second specialised filter to selectively extract particular substances while returning more of the beneficial plasma proteins to the patient. This approach offers greater precision when a specific toxin or antibody fraction is the primary target.
A note on evidence and eligibility
Toxin removal via TPE is supported by case reports, registry data, and mechanistic studies rather than large randomised trials. At Reborne, this pathway is offered within a carefully governed clinical framework, with full transparency about the current state of evidence. A comprehensive diagnostic workup, including validated laboratory testing for heavy metals and relevant toxin panels, is required before any treatment is recommended. All treatments are individually prescribed by our clinical team.
Is TPE Right for Me?
TPE is a medically prescribed treatment, not a wellness add-on. Before any recommendation is made, you will undergo a comprehensive clinical assessment with one of our specialist physicians. This includes a full review of your medical history, current health status, and relevant diagnostic results.
No client proceeds to TPE without a thorough clinical evaluation. Our team will always discuss the potential benefits, risks, and alternatives with you before any treatment plan is agreed.
To find out whether TPE may be appropriate for you, please contact us to arrange a consultation.
9 Queen Anne Street, Marylebone, London W1G 9HW
+44 203 839 5051 | info@rebornelongevity.com